[go: up one dir, main page]

WO2007055760A3 - Composition de proteine pour favoriser la cicatrisation des plaies et la regeneration de la peau - Google Patents

Composition de proteine pour favoriser la cicatrisation des plaies et la regeneration de la peau Download PDF

Info

Publication number
WO2007055760A3
WO2007055760A3 PCT/US2006/030059 US2006030059W WO2007055760A3 WO 2007055760 A3 WO2007055760 A3 WO 2007055760A3 US 2006030059 W US2006030059 W US 2006030059W WO 2007055760 A3 WO2007055760 A3 WO 2007055760A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
methods
wound healing
protein composition
promoting wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/030059
Other languages
English (en)
Other versions
WO2007055760A2 (fr
Inventor
Zoltan Kiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Essential SkinCare LLC
Original Assignee
Essential SkinCare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Essential SkinCare LLC filed Critical Essential SkinCare LLC
Priority to EP06789173A priority Critical patent/EP1942928A2/fr
Publication of WO2007055760A2 publication Critical patent/WO2007055760A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007055760A3 publication Critical patent/WO2007055760A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés et régimes pour stimuler la prolifération et inhiber la mort des cellules de peau dans de la peau saine ou malade présentant des plaies ou non, ou transplantée et des suspensions de cellules de peau. Les procédés et régimes comprennent une étape d'administration à une région de peau d'hôte et/ou de peau transplantée d'une combinaison de lactoferrine et de phosphatase alcaline telle que la phosphatase alcaline placentaire. Les composants actifs peuvent être administrés localement, par injection, ou par d'autres moyens adaptés. En plus d'améliorer la qualité de la peau, les procédés décrits peuvent également être efficaces pour réduire l'inflammation et l'infection microbienne dans la peau. Des modes de réalisation de l'invention concernent en outre des compositions adaptées pour être utilisées dans les procédés décrits.
PCT/US2006/030059 2005-10-31 2006-08-02 Composition de proteine pour favoriser la cicatrisation des plaies et la regeneration de la peau Ceased WO2007055760A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06789173A EP1942928A2 (fr) 2005-10-31 2006-08-02 Composition de proteine pour favoriser la cicatrisation des plaies et la regeneration de la peau

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73216505P 2005-10-31 2005-10-31
US60/732,165 2005-10-31

Publications (2)

Publication Number Publication Date
WO2007055760A2 WO2007055760A2 (fr) 2007-05-18
WO2007055760A3 true WO2007055760A3 (fr) 2009-05-07

Family

ID=38023729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/030059 Ceased WO2007055760A2 (fr) 2005-10-31 2006-08-02 Composition de proteine pour favoriser la cicatrisation des plaies et la regeneration de la peau

Country Status (2)

Country Link
EP (1) EP1942928A2 (fr)
WO (1) WO2007055760A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5869219B2 (ja) 2007-08-16 2016-02-24 レメドー バイオメッド リミテッド 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物
US8784805B2 (en) 2008-02-29 2014-07-22 Alloksys Life Sciences B.V. Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
EP3600257B8 (fr) 2017-03-21 2023-06-21 Theriva Biologics, Inc. Formulations de phosphatase alcaline
AU2019207600B2 (en) 2018-01-09 2025-01-09 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2019183208A1 (fr) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Formulations de phosphatase alcaline intestinale
US12318434B2 (en) 2019-05-06 2025-06-03 Theriva Biologics, Inc. Alkaline phosphate-based oncology treatments

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409332A (en) * 1982-01-12 1983-10-11 Jefferies Steven R Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
US5561109A (en) * 1990-11-13 1996-10-01 Santen Pharmaceutical Co., Ltd. Method for the healing of wounds caused by corneal injury
US6277387B1 (en) * 1994-12-28 2001-08-21 L'oreal Use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF αantagonist in a cosmetic, pharmaceutical or dermatological composition and composition obtained
US20020127216A1 (en) * 2001-03-09 2002-09-12 Zoltan Kiss Compositions and methods for stimulating wound healing and fibroblast proliferation
US6645936B1 (en) * 1995-05-08 2003-11-11 Santen Pharmaceutical Co., Ltd. Reducing postoperative astigmatism
US20050048046A1 (en) * 2003-09-02 2005-03-03 Zoltan Kiss Use of placental alkaline phosphatase to promote skin cell proliferation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409332A (en) * 1982-01-12 1983-10-11 Jefferies Steven R Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
US5561109A (en) * 1990-11-13 1996-10-01 Santen Pharmaceutical Co., Ltd. Method for the healing of wounds caused by corneal injury
US6277387B1 (en) * 1994-12-28 2001-08-21 L'oreal Use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF αantagonist in a cosmetic, pharmaceutical or dermatological composition and composition obtained
US6645936B1 (en) * 1995-05-08 2003-11-11 Santen Pharmaceutical Co., Ltd. Reducing postoperative astigmatism
US20020127216A1 (en) * 2001-03-09 2002-09-12 Zoltan Kiss Compositions and methods for stimulating wound healing and fibroblast proliferation
US20050048046A1 (en) * 2003-09-02 2005-03-03 Zoltan Kiss Use of placental alkaline phosphatase to promote skin cell proliferation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEINBERG, E. D.: "Human lactoferrin: a novel therapeutic with broad spectrum potential.", THE JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 53, no. 10, 2001, pages 1303 - 1310 *

Also Published As

Publication number Publication date
EP1942928A2 (fr) 2008-07-16
WO2007055760A2 (fr) 2007-05-18

Similar Documents

Publication Publication Date Title
EP2236153A3 (fr) Composés et méthodes pour le traitement de maladies cardiaques
EP2243826A3 (fr) Cellules souches mésenchymateuses et utilisations associées
WO2010124280A3 (fr) Onguent topique à base de sérum-albumine humaine pour le traitement de l'acné, du psoriasis, de la toxicité induite par egfr, le vieillissement prématuré de la peau et autres affections cutanées
WO2009136291A3 (fr) Extraits cellulaires
WO2007038686A3 (fr) Preparations de membrane amniotique et compositions purifiees, et procedes d'utilisation
BR0317564A (pt) Compostos, composições e métodos para tratar doenças causadas por bactérias ou fungos
WO2006007384A3 (fr) Antibiotiques contenant des complexes de l'acide borinique, et leur procede d'utilisation
WO2004096224A3 (fr) Combinaisons pour traiter des maladies impliquant la proliferation cellulaire, la migration ou l'apoptose de cellules du myelome ou l'angiogenese
WO2009045360A3 (fr) Elimination des tumeurs au moyen d'un perfusat placentaire humain et de cellules tueuses naturelles intermediaires provenant d'un placenta humain
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
WO2007044084A3 (fr) Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation
WO2006044860A3 (fr) Composes de thiadiazole et leurs procedes d'utilisation
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
CA2388939A1 (fr) Traitements therapeutiques pour des deficiences en cellules sanguines
WO2008079270A3 (fr) Coadministration d'alpha-foetoprotéine et d'un agent immunomodulateur pour traiter la sclérose en plaques
WO2008118370A3 (fr) Traitement hyperbare pour la cicatrisation d'une plaie
WO2007009019A3 (fr) Compositions proteiques favorisant la cicatrisation de lesions et la regeneration cutanee
ATE383854T1 (de) Kombination ausgewählter opioide mit muscarin- antagonisten zur therapie der harninkontinenz
WO2008143705A3 (fr) Procédés et compositions pour l'inactivation rapide de protéines
WO2007055760A3 (fr) Composition de proteine pour favoriser la cicatrisation des plaies et la regeneration de la peau
MY158929A (en) Pharmaceutical combination
WO2005060960A3 (fr) Utilisation de l'histamine pour le traitement de maladies osseuses
WO2005094554A3 (fr) Agents, methodes et traitements therapeutiques
WO2010132690A3 (fr) Compositions et procédés favorisant la régénération des tissus et la cicatrisation des plaies
WO2009106715A3 (fr) Peptide derive d'une proteine de la famille des aquaporines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006789173

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE